The Latest Cardiac and Vascular News
A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary […]
Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022 BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease […]
CAUTION: Investigational device. Limited by United States law to investigational use. W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior vena cava occlusive disease. FLAGSTAFF, Ariz., Oct. 28, 2022 /PRNewswire/ — W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular […]
IRVINE, Calif., Oct. 27, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion grew 1 percent; constant currency1 sales grew 7 percent Q3 TAVR sales grew 1 percent; constant currency sales grew 6 percent Q3 EPS of $0.55; adjusted1 EPS […]
BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q3 2022 Financial Results Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021 Op. income $6.2mm, -32% Op. margin of […]
Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stopped Cash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical […]
GENT, Belgium–(BUSINESS WIRE)–FEops, a cloud-based digital health player in the structural heart space, announces that it has secured a convertible loan of EUR 3.3m from its current investors and the EIC Fund in preparation of a larger capital round. “We were already very proud to be selected in the highly […]
Transformative XO Angioplasty Platform Expands with Low-Profile 2.2F and 3.8F Rapid-Exchange (RX) with the Ability to Treat Up to 20cm Lesions with (1) Inflation SALT LAKE CITY, Oct. 27, 2022 /PRNewswire/ — Transit Scientific, a pioneer in developing medical devices to treat calcified cardiovascular disease, dilate stenosed intimal hyperplasia, and access, cross, […]
This registry will confirm safety and performance of the VBX Stent Graft in peripheral vessels in patients who require interventional treatment in a variety of applications and diseases. PUTZBRUNN, Germany, Oct. 27, 2022 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore) announced the completion of target enrollment in the EXPAND Post-Market Registry […]
—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch— —Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of Brensocatib in First Quarter of 2023 and […]
